BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN BEGIN:VEVENT UID:106@canceropole-clara.com DTSTART:20250424T150000Z DTEND:20250424T154500Z DTSTAMP:20250328T095858Z URL:https://www.canceropole-clara.com/events/webinar-in-conversation-with- itcc-p4/ SUMMARY:Webinar "In conversation with… ITCC-P4" DESCRIPTION:\n\nOn April 24\, 2025 from 15:00 CET to 15:45 CET\, the Innova tive Health Initiative is organising an online event ‘In conversation wi th… ITCC-P4’ that will focus on the tools that the project developed t o help accelerate childhood cancer research.\n\nIHI’s senior scientific project manager\, Nathalie Seigneuret\, will moderate the discussion betwe en:\n\n Gilles Vassal\, chief operating officer of ITCC-P4 and paediatric oncologist at Gustave Roussy Comprehensive Cancer Center\n Lou Stancato\ , VP of enabling technologies and leader of paediatric rare diseases at In diana Biosciences Research Institute and adjunct clinical assistant profes sor of pediatrics at the Indiana University School of Medicine\n Nicole S cobie\, patient representative\, chair of Accelerate\, board member of the Coalition Against Childhood Cancer (CAC2)\, and president emeritus at Zo é4Life\n\nRegister here >\;>\;\n\nAbout the ITCC-P4 project \n\nCance r is still the leading cause of death by disease seen in children in Europ e. Yet childhood cancers are relatively rare and are different in nature t o most cancers found in adults\, presenting particular challenges to cance r researchers.\n\nThe ITCC-P4 project has delivered a system composed of t ools that can help researchers from both the public and private sector to identify promising molecules that could form the basis of new drugs to tre at childhood cancer. This will help researchers to prioritise which drug c andidates to test in children and accelerate the time it takes for those m edicines to reach the clinic.\n\nThe toolkit includes validated models\, a unique database outlining comprehensive molecular data about childhood ca ncers\, an international consensus on the preclinical data needed to suppo rt paediatric drug development\, and a new methodology to define the relev ance of certain drug targets based on literature analysis. One of the key results was the development of PDX models of many childhood cancers\, from the more common forms of cancer to relapses and rare cancers. PDX models are made from a combination of patient-derived tumour tissue and mouse mod els\, and they have proven to be an effective way of studying cancer in ad ults but are not yet widely used in childhood cancer research.\n\nITCC-P4 has set up a new non-profit organisation which will continue to provide th ese vital tools and expertise to cancer researchers going forwards.\n\nFin d out more and register here >\;>\;\n\nVisit the ITCC-P4 website >\; >\; CATEGORIES:Autres événements END:VEVENT END:VCALENDAR